Pfizer announced its intention to sell approximately 700 million ordinary shares in Haleon, the British consumer healthcare group. This transaction will reduce Pfizer's stake in Haleon to about 7.3%.
This planned divestiture represents a continued effort by Pfizer to streamline its portfolio and focus on its core biopharmaceutical business. The sale is expected to generate additional capital for the company.
The reduction of its stake in Haleon aligns with Pfizer's strategic priorities to optimize its asset base and enhance financial flexibility for future investments in its pipeline and growth drivers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.